Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat

Journal of Internal Medicine

Volumn 260, Issue 4, 2006, Pages 388-398

  Poston, W S C ^a,c   Haddock, C K ^a   Pinkston, M M ^a   Pace, P ^b   Reeves, R S ^b   Karakoc, N ^b   Jones, P ^b   Foreyt, J P ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Behavioural medicine; Obesity; Primary care; Weight loss

Indexed keywords

FENFLURAMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABNORMAL FECES; ADULT; ARTICLE; BACKACHE; BLOOD PRESSURE; BODY MASS; BRONCHITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EAR INFECTION; FECES INCONTINENCE; FEMALE; FLATULENCE; FOOT EDEMA; GASTRITIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INFLUENZA; INSOMNIA; INTESTINAL DYSMOTILITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL SCHOOL; MENOPAUSAL SYNDROME; MYALGIA; MYCOSIS; NAUSEA; OBESITY; PATIENT COMPLIANCE; PATIENT COUNSELING; PNEUMONIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SORE THROAT; STRESS; SWELLING; THYROID NODULE; TOOTH PAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO; WEIGHT CHANGE; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; COUNSELING; HUMANS; LACTONES; LIFE STYLE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; PATIENT DROPOUTS; PRIMARY HEALTH CARE; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 33748581034     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01702.x     Document Type: Article

References (30)

1. Logue E, Sutton K, Jarjoura D, Smucker W. Obesity management in primary care: assessment of readiness to change among 284 family practice patients. J Am Board Fam Pract 2000; 13: 164-71.
2. Avenell A, Broom J, Brown TJ et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: 1-182.
3. Block JP, DeSalvo KB, Fisher WP. Are physicians equipped to address the obesity epidemic? Knowledge and attitudes of internal medicine residents. Prev Med 2003; 36: 669-75.
4. Foster GD, Wadden TA, Makris AP et al. Primary care physicians' attitudes about obesity and its treatment. Obes Res 2003; 11: 1168-77.
5. Lyznicki JM, Young DC, Riggs JA, Davis RM. Obesity: assessment and management in primary care. Am Fam Physician 2001; 63: 2185-96.
6. Wadden TA, Berkowitz RI, Vogt RA et al. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. Obes Res 1997; 5: 218-26.
7. Wadden TA, Berkowitz RI, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-20.
8. Feigenbaum A, Pasternak S, Zusk E, Sarid M, Vinker S. Influence of intense multidisciplinary follow-up and orlisat on weight reduction in a primary care setting. BMC Fam Pract 2005; 6: 5.
9. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160-7.
10. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K. Weight reduction by sibutramine in obese subjects in primary care medicine: The SAT Study. Exp Clin Endocrinol Diabetes 2004; 112: 201-7.
11. Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med 2000; 248: 245-54.
12. McMahon GF, Fujioka K, Singh BN et al. Efficacy and safety of sibutramine in obese White and African American patients with hypertension: a 1-year double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-91.
13. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001; 161: 218-27.
14. Craighead LW, Stunkard AJ, O'Brien RM. Behavior therapy and pharmacotherapy for obesity. Arch Gen Psychiatry 1981; 38: 763-8.
15. Moher D, Schulz KF, Altman D. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987-91.
16. Bandura A. Social Foundations of Thought and Action. Englewood Cliffs, NJ: Prentice Hall, 1986.
17. Brownell KD. The LEARN Program for Weight Control: Lifestyle, Exercise, Attitudes, Relationships, Nutrition. Dallas, TX: American Health Publishing Company, 2000.
18. Poston WSC, Foreyt JP. Successful management of the obese patient. Am Fam Physician 2000; 61: 3615-22.
19. Cormillot A, Fuchs A. The possible weight. Int J Obes Relat Metab Disord 1990; 14(Suppl. 2): 10 (Abstract).
20. Black HS, Herd JA, Goldberg LH et al. Effect of a low fat diet on the incidence of actinic keratosis. N Engl J Med 1994; 330: 1272-5.
21. Black HS, Thornby JI, Wolf JE et al. Evidence that a low-fat diet reduces the occurrence of non-melanoma skin cancer. Int J Cancer 1995; 62: 165-9.
22. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
23. Torgerson JS, Boldrin MN, Hauptman J, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004; 27: 155-61.
24. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointesitinal lipase. Int J Obes Relat Metab Disord 2000; 24: 306-13.
25. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin N Am 2000; 84: 441-61.
26. Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-73.
27. Poston WSC, Haddock CK, Dill PL, Thayer B, Foreyt JP. Lifestyle treatments in randomized clinical trials of pharmacotherapies for obesity. Obes Res 2001; 9: 552-63.
28. Hollis JF, Lichtenstein E, Vogt TM et al. A nurse-assisted counseling for smokers in primary care. Ann Intern Med 1993; 118: 521-5.
29. Muramoto ML, Connolly T, Strayer LJ et al. Tobacco cessation skills certification in Arizona: application of a statewide model for diffusion of evidence based practice guidelines. Tob Control 2000; 9: 408-14.
30. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003; 27: 1437-46.